TRex Bio (NASDAQ:TRXB) Coverage Initiated by Analysts at Evercore

Evercore began coverage on shares of TRex Bio (NASDAQ:TRXB) in a research report sent to investors on Tuesday,Zacks reports. The firm issued a strong-buy rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. JPMorgan Chase & Co. began coverage on shares of TRex Bio in a report on Tuesday. They issued an “overweight” rating and a $20.00 price target on the stock. Wedbush initiated coverage on shares of TRex Bio in a research note on Monday. They set an “outperform” rating and a $30.00 price objective for the company. Stifel Nicolaus started coverage on shares of TRex Bio in a report on Tuesday. They set a “buy” rating and a $39.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of TRex Bio in a research note on Tuesday. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, TRex Bio currently has an average rating of “Buy” and a consensus target price of $29.67.

TRex Bio Stock Down 1.3%

TRXB stock opened at $13.55 on Tuesday. TRex Bio has a twelve month low of $12.50 and a twelve month high of $16.56.

Insiders Place Their Bets

In other TRex Bio news, major shareholder Alexandria Venture Investments bought 178,571 shares of the firm’s stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the purchase, the insider directly owned 1,346,501 shares of the company’s stock, valued at $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.